ZGNX News and Press, Zogenix Inc. From 08/06/21

Zogenix, Inc. (ZGNX) Q2 2021 Results Conference Call August 05, 2021 04:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors Dr. Stephen Farr - CEO Ashish Sagrolikar - Chief Commercial Officer Michael Smith - CFO Conference Call Participants Paul Matteis - Stifel Marc Goodman - SVB ...

Earnings news sparked big moves in individual stocks during Friday's midday trading. Synaptics (NASDAQ:SYNA) and LiveRamp (NYSE:RAMP) both advanced following the release of their quarterly results. Meanwhile, financial figures sent Zogenix (NASDAQ:ZGNX) and Zynga (NASDAQ:ZNGA) reeling. Dicern...

Zogenix (NASDAQ:ZGNX): Q2 GAAP EPS of -$1.05 misses by $0.12. Revenue of $18.79M (+1724.3% Y/Y) beats by $2.19M. As of June 30, 2021, the Company had $393.0 million in cash, cash equivalents, and marketable securities, compared to $505.1 million at December 31, 2...

Commercial launches of FINTEPLA ® in the U.S. and Europe progressing strongly, with total net product sales of $17.5 million and total revenue of $18.8 million in the second quarter, representing quarter-over-quarter increases of 42% and 37%, respect...

EMERYVILLE, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, ...

Today, we have our "Double Down or Diversify" series. We have 13 new ideas that contributors have chosen for the second half of the contest. With a heavy focus on biotech, commodities, and energy - there also are ideas for investors who focus on tech, value, and dividends. F...

EMERYVILLE, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that it will report its financial results for the second quarter ended June 30, 2021 and host a corpor...

In Epilepsy & Behavior editorial, authors write that FINTEPLA data demonstrate “unprecedented level of seizure control” for treated patients living with Dravet syndrome, a severe, debilitating childhood-onset epilepsy. Authors also recognize FINTEPLA for ac...

Since Fintepla's launch, shares of Zogenix have continued to slide. This is, primarily, due to unimpressive Fintepla adoption two quarters in and an underperforming biotechnology sector. Last quarter, Fintepla saw 53% quarter-over-quarter growth, with revenues coming in at $...

EMERYVILLE, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Zogenix, a global biopharmaceutical company developing rare disease therapies, and ten U.S. advocacy groups today announced the launch of VIP Siblings , a new website and suite of materials created to celebrate and ...